The evolution of antipsychotic switch and polypharmacy in natural practice - A longitudinal perspective

Chisa Tsutsumi, Hiroyuki Uchida, Takefumi Suzuki, Koichiro Watanabe, Hiroyoshi Takeuchi, Shinichiro Nakajima, Yoshie Kimura, Yuichiro Tsutsumi, Koichi Ishii, Yasushi Imasaka, Shitij Kapur

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Objective: Most patients with schizophrenia first start with a single antipsychotic, and yet most finally end up 'switching' or using 'polypharmacy'. The objective of this study was to examine the evolution of antipsychotic switch and polypharmacy in the real-world from a longitudinal perspective. Methods: A systematic review of longitudinal antipsychotic prescriptions in 300 patients with schizophrenia (ICD-10) for up to 2. years after their first visit to one of the 4 participating psychiatric clinics in Tokyo, Japan between January, 2007 and June, 2008, was conducted. Reasons for prescription change were also examined. The evolution of switching and polypharmacy was studied, and prescribed doses were compared to suggested dose ranges by the Texas Medication Algorithm Project (TMAP). Results: 208 patients started their antipsychotic treatment with monotherapy. 34.1% of the patients gave up monotherapy with an initial antipsychotic to move to antipsychotic switch (27.4%) and/or polypharmacy (17.8%) within 2. years. The main reason for antipsychotic switch was 'ineffectiveness'; interestingly, this happened despite the fact that the monotherapy dose was below the recommended range in 47.4% of the antipsychotic switch. In a subgroup of 100 patients who started as antipsychotic-free, 2-year prevalence rates of switching and antipsychotic polypharmacy were 27.0% and 18.0%, respectively, and polypharmacy was resorted to after a median of 1 antipsychotic had been tried for 84. days (median). Conclusions: These findings raise a concern that physicians may perform an antipsychotic switch without exploring the entire dose range and resort to antipsychotic polypharmacy without trying an adequate number of antipsychotics.

Original languageEnglish
Pages (from-to)40-46
Number of pages7
JournalSchizophrenia Research
Volume130
Issue number1-3
DOIs
Publication statusPublished - 2011 Aug

Fingerprint

Polypharmacy
Antipsychotic Agents
Prescriptions
Schizophrenia
Tokyo
International Classification of Diseases

Keywords

  • Antipsychotic
  • Dose
  • Polypharmacy
  • Prescription
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

The evolution of antipsychotic switch and polypharmacy in natural practice - A longitudinal perspective. / Tsutsumi, Chisa; Uchida, Hiroyuki; Suzuki, Takefumi; Watanabe, Koichiro; Takeuchi, Hiroyoshi; Nakajima, Shinichiro; Kimura, Yoshie; Tsutsumi, Yuichiro; Ishii, Koichi; Imasaka, Yasushi; Kapur, Shitij.

In: Schizophrenia Research, Vol. 130, No. 1-3, 08.2011, p. 40-46.

Research output: Contribution to journalArticle

Tsutsumi, Chisa ; Uchida, Hiroyuki ; Suzuki, Takefumi ; Watanabe, Koichiro ; Takeuchi, Hiroyoshi ; Nakajima, Shinichiro ; Kimura, Yoshie ; Tsutsumi, Yuichiro ; Ishii, Koichi ; Imasaka, Yasushi ; Kapur, Shitij. / The evolution of antipsychotic switch and polypharmacy in natural practice - A longitudinal perspective. In: Schizophrenia Research. 2011 ; Vol. 130, No. 1-3. pp. 40-46.
@article{e3c035e448fa433880a16ab48d3b74e2,
title = "The evolution of antipsychotic switch and polypharmacy in natural practice - A longitudinal perspective",
abstract = "Objective: Most patients with schizophrenia first start with a single antipsychotic, and yet most finally end up 'switching' or using 'polypharmacy'. The objective of this study was to examine the evolution of antipsychotic switch and polypharmacy in the real-world from a longitudinal perspective. Methods: A systematic review of longitudinal antipsychotic prescriptions in 300 patients with schizophrenia (ICD-10) for up to 2. years after their first visit to one of the 4 participating psychiatric clinics in Tokyo, Japan between January, 2007 and June, 2008, was conducted. Reasons for prescription change were also examined. The evolution of switching and polypharmacy was studied, and prescribed doses were compared to suggested dose ranges by the Texas Medication Algorithm Project (TMAP). Results: 208 patients started their antipsychotic treatment with monotherapy. 34.1{\%} of the patients gave up monotherapy with an initial antipsychotic to move to antipsychotic switch (27.4{\%}) and/or polypharmacy (17.8{\%}) within 2. years. The main reason for antipsychotic switch was 'ineffectiveness'; interestingly, this happened despite the fact that the monotherapy dose was below the recommended range in 47.4{\%} of the antipsychotic switch. In a subgroup of 100 patients who started as antipsychotic-free, 2-year prevalence rates of switching and antipsychotic polypharmacy were 27.0{\%} and 18.0{\%}, respectively, and polypharmacy was resorted to after a median of 1 antipsychotic had been tried for 84. days (median). Conclusions: These findings raise a concern that physicians may perform an antipsychotic switch without exploring the entire dose range and resort to antipsychotic polypharmacy without trying an adequate number of antipsychotics.",
keywords = "Antipsychotic, Dose, Polypharmacy, Prescription, Schizophrenia",
author = "Chisa Tsutsumi and Hiroyuki Uchida and Takefumi Suzuki and Koichiro Watanabe and Hiroyoshi Takeuchi and Shinichiro Nakajima and Yoshie Kimura and Yuichiro Tsutsumi and Koichi Ishii and Yasushi Imasaka and Shitij Kapur",
year = "2011",
month = "8",
doi = "10.1016/j.schres.2011.05.013",
language = "English",
volume = "130",
pages = "40--46",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - The evolution of antipsychotic switch and polypharmacy in natural practice - A longitudinal perspective

AU - Tsutsumi, Chisa

AU - Uchida, Hiroyuki

AU - Suzuki, Takefumi

AU - Watanabe, Koichiro

AU - Takeuchi, Hiroyoshi

AU - Nakajima, Shinichiro

AU - Kimura, Yoshie

AU - Tsutsumi, Yuichiro

AU - Ishii, Koichi

AU - Imasaka, Yasushi

AU - Kapur, Shitij

PY - 2011/8

Y1 - 2011/8

N2 - Objective: Most patients with schizophrenia first start with a single antipsychotic, and yet most finally end up 'switching' or using 'polypharmacy'. The objective of this study was to examine the evolution of antipsychotic switch and polypharmacy in the real-world from a longitudinal perspective. Methods: A systematic review of longitudinal antipsychotic prescriptions in 300 patients with schizophrenia (ICD-10) for up to 2. years after their first visit to one of the 4 participating psychiatric clinics in Tokyo, Japan between January, 2007 and June, 2008, was conducted. Reasons for prescription change were also examined. The evolution of switching and polypharmacy was studied, and prescribed doses were compared to suggested dose ranges by the Texas Medication Algorithm Project (TMAP). Results: 208 patients started their antipsychotic treatment with monotherapy. 34.1% of the patients gave up monotherapy with an initial antipsychotic to move to antipsychotic switch (27.4%) and/or polypharmacy (17.8%) within 2. years. The main reason for antipsychotic switch was 'ineffectiveness'; interestingly, this happened despite the fact that the monotherapy dose was below the recommended range in 47.4% of the antipsychotic switch. In a subgroup of 100 patients who started as antipsychotic-free, 2-year prevalence rates of switching and antipsychotic polypharmacy were 27.0% and 18.0%, respectively, and polypharmacy was resorted to after a median of 1 antipsychotic had been tried for 84. days (median). Conclusions: These findings raise a concern that physicians may perform an antipsychotic switch without exploring the entire dose range and resort to antipsychotic polypharmacy without trying an adequate number of antipsychotics.

AB - Objective: Most patients with schizophrenia first start with a single antipsychotic, and yet most finally end up 'switching' or using 'polypharmacy'. The objective of this study was to examine the evolution of antipsychotic switch and polypharmacy in the real-world from a longitudinal perspective. Methods: A systematic review of longitudinal antipsychotic prescriptions in 300 patients with schizophrenia (ICD-10) for up to 2. years after their first visit to one of the 4 participating psychiatric clinics in Tokyo, Japan between January, 2007 and June, 2008, was conducted. Reasons for prescription change were also examined. The evolution of switching and polypharmacy was studied, and prescribed doses were compared to suggested dose ranges by the Texas Medication Algorithm Project (TMAP). Results: 208 patients started their antipsychotic treatment with monotherapy. 34.1% of the patients gave up monotherapy with an initial antipsychotic to move to antipsychotic switch (27.4%) and/or polypharmacy (17.8%) within 2. years. The main reason for antipsychotic switch was 'ineffectiveness'; interestingly, this happened despite the fact that the monotherapy dose was below the recommended range in 47.4% of the antipsychotic switch. In a subgroup of 100 patients who started as antipsychotic-free, 2-year prevalence rates of switching and antipsychotic polypharmacy were 27.0% and 18.0%, respectively, and polypharmacy was resorted to after a median of 1 antipsychotic had been tried for 84. days (median). Conclusions: These findings raise a concern that physicians may perform an antipsychotic switch without exploring the entire dose range and resort to antipsychotic polypharmacy without trying an adequate number of antipsychotics.

KW - Antipsychotic

KW - Dose

KW - Polypharmacy

KW - Prescription

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=79960335818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960335818&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2011.05.013

DO - 10.1016/j.schres.2011.05.013

M3 - Article

C2 - 21624824

AN - SCOPUS:79960335818

VL - 130

SP - 40

EP - 46

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

IS - 1-3

ER -